domingo, 8 de septiembre de 2013

Germline genetic variants in ABCB1, ABCC1... [Pharmacogenomics J. 2013] - PubMed - NCBI

Germline genetic variants in ABCB1, ABCC1... [Pharmacogenomics J. 2013] - PubMed - NCBI

Pharmacogenomics J. 2013 Sep 3. doi: 10.1038/tpj.2013.32. [Epub ahead of print]

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.


Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.


Hematological and gastrointestinal toxicities are common among patients treated with cyclophosphamide and doxorubicin for breast cancer. To examine whether single-nucleotide polymorphisms (SNPs) in key pharmacokinetic genes were associated with risk of hematological or gastrointestinal toxicity, we analyzed 78 SNPs in ABCB1, ABCC1 and ALDH1A1 in 882 breast cancer patients enrolled in the SWOG trial S0221 and treated with cyclophosphamide and doxorubicin. A two-SNP haplotype in ALDH1A1 was associated with an increased risk of grade 3 and 4 hematological toxicity (odds ratio=1.44, 95% confidence interval=1.16-1.78), which remained significant after correction for multiple comparisons. In addition, four SNPs in ABCC1 were associated with gastrointestinal toxicity. Our findings provide evidence that SNPs in pharmacokinetic genes may have an impact on the development of chemotherapy-related toxicities. This is a necessary first step toward building a clinical tool that will help assess risk of adverse outcomes before undergoing chemotherapy.The Pharmacogenomics Journal advance online publication, 3 September 2013; doi:10.1038/tpj.2013.32.
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario